Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.

被引：0
|
作者：
Li, Regina
Mai, Helen
Chiasson, Kaitlyn
Trudeau, Maureen E.
Chan, Kelvin K.
Cheung, Matthew C.
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Canadian Agcy Drugs & Technol Hlth, Pan Canadian Oncol Drug Review, Toronto, ON, Canada
[3] CADTH, Ottawa, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[5] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14133
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Total and cancer-attributable phase-based costs for childhood cancer care: A population-based study in British Columbia, Canada.
    McBride, Mary L.
    Duncan, Ross
    Bremner, Karen
    De Oliveira, Claire
    Liu, Ning
    Nathan, Paul C.
    Rogers, Paul C.
    Peacock, Stuart
    Krahn, Murray Dale
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (05)
  • [22] ONCOLOGY DRUGS WITHOUT PHASE III DATA: COMPARISON OF REIMBURSEMENT RECOMMENDATIONS ISSUED BY THE CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH (CADTH), AND THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)
    Singh, S.
    Hachborn, G.
    Jarrett, K.
    Pericleous, L.
    Benyo, S.
    Maoloni, M.
    VALUE IN HEALTH, 2022, 25 (01) : S174 - S175
  • [23] Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau, Catherine Y.
    Rawson, Nigel S. B.
    CURRENT ONCOLOGY, 2024, 31 (09) : 5599 - 5607
  • [24] Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials
    Molfino, Alessio
    Amabile, Maria Ida
    Giorgi, Antonella
    Monti, Massimo
    D'Andrea, Vito
    Muscaritoli, Maurizio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 733 - 740
  • [25] The Fourth Hurdle Commentary on "Weighing Of Evidence By Health Technology Assessment Bodies: Retrospective Study Of Reimbursement Recommendations For Conditionally Approved Drugs" by Vreman et al.
    Honig, Peter K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (03) : 561 - 562
  • [26] Occupational exposure to asbestos and manmade vitreous fibers, and risk of lung cancer: Evidence from two case-control studies in Montreal, Canada.
    Pintos, J.
    Parent, M-E
    Rousseau, M-C
    Siemiatycki, J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 165 (11) : S102 - S102
  • [27] How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?
    Pratte, Michael
    Ganeshamoorthy, Sylviya
    Carlisle, Benjamin
    Kimmelman, Jonathan
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (12) : 3370 - 3375
  • [28] PHASE-II STUDY OF TIAZOFURIN IN COLORECTAL-CANCER - A NATIONAL-CANCER-INSTITUTE-OF-CANADA STUDY
    MAROUN, JA
    EISENHAUER, E
    CRIPPS, C
    MAKSYMIUK, A
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1297 - 1298
  • [29] A funding program for new anti-cancer drugs in Ontario, Canada, based on quality of evidence and a hierarchy of outcomes
    Evans, WK
    Pater, J
    Nefsky, N
    Brouwers, M
    Browman, G
    Cowan, D
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 300 - 301
  • [30] Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group
    Trudeau, ME
    Eisenhauer, EA
    Higgins, BP
    Letendre, F
    Lofters, WS
    Norris, BD
    Vandenberg, TA
    Delorme, F
    Muldal, AM
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 422 - 428
12345